INTRODUCTION: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in kidney transplant recipient (KTR). There is a dearth of standardized guidelines on optimal cardiovascular evaluation of transplant candidates. METHODS: This single-center cohort study aims to determine the effectiveness of our standardized risk-stratified pretransplant cardiovascular screening protocol, which includes coronary angiography (CAG), in identifying advanced CVD, the proper pretransplant management of which could lead to a reduction in the incidence of major cardiac events (MACE) in the early posttransplant period. RESULTS: Out of the total 776 KTR transplanted between 2017 and 2019, CAG was performed on 541 patients (69.7%), of whom 22.4% were found to have obstructive coronary artery disease (CAD). Asymptomatic obstructive CAD was observed in 70.2% of cases. In 73.6% of cases, CAG findings resulted in myocardial revascularization. MACE occurred in 5.6% (N = 44) of the 23 KTR with pretransplant CVD and 21 without pretransplant CVD. KTR with posttransplant MACE occurrence had significantly worse kidney graft function at the first year posttransplant (p = 0.00048) and worse patient survival rates (p = 0.0063) during the 3-year follow-up period compared with KTR without MACE. After adjustment, the independent significant factors for MACE were arrhythmia (HR 2.511, p = 0.02, 95% CI 1.158-5.444), pretransplant history of acute myocardial infarction (HR 0.201, p = 0.046, 95% CI 0.042-0.970), and pretransplant myocardial revascularization (HR 0.225, p = 0.045, 95% CI 0.052-0.939). CONCLUSION: Asymptomatic CVD is largely prevalent in KTR. Posttransplant MACE has a negative effect on grafts and patient outcomes. Further research is needed to assess the benefits of pretransplant myocardial revascularization in asymptomatic kidney transplant candidates.

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czech Republic

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic

See more in PubMed

Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end stage renal disease patients. Am J Kidney Dis. (2001) 38:S26–9. 10.1053/ajkd.2001.27392 PubMed DOI

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med. (2004) 351:1296–305. 10.1056/NEJMoa041031 PubMed DOI

Ponticelli C, Campise MR. The inflammatory state is a risk factor for cardiovascular disease and graft fibrosis in kidney transplantation. Kidney Int. (2021) 100(3):536–45. 10.1016/j.kint.2021.04.016 PubMed DOI

Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease. Circulation. (2021) 143(11):1157–72. 10.1161/CIRCULATIONAHA.120.050686 PubMed DOI PMC

Loupy A, Vernerey D, Viglietti D, Aubert O, Van Huyen JPD, Empana JP, et al. Determinants and outcomes of accelerated arteriosclerosis: major impact of circulating antibodies. Circ Res . 2015;117(5):470–82. 10.1161/CIRCRESAHA.117.306340 PubMed DOI

Rodrigues-Diez R, González-Guerrero C, Ocaña-Salceda C, Rodrigues-Diez RR, Egido J, Ortiz A. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. Sci Rep. (2016) 6:27915. 10.1038/srep27915 PubMed DOI PMC

Hage FG, Smalheiser S, Zoghbi GJ, Perry GJ, Deierhoi M, Warnock D, et al. Predictors of survival in patients with end-stage renal disease evaluated for kidney transplantation. Am J Cardiol. (2007) 100(6):1020–5. 10.1016/j.amjcard.2007.04.045 PubMed DOI

Aalten J, Peeters SA, van der Vlugt MJ, Hoitsma AJ. Is standardized cardiac assessment of asymptomatic high-risk renal transplant candidates beneficial? Nephrol Dial Transplant. (2011) 26:3006–12. 10.1093/ndt/gfq822 PubMed DOI

Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. (2007) 356(15):1503–16. 10.1056/NEJMoa070829 PubMed DOI

Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. Circulation. (2012) 126(5):617–63. 10.1161/CIR.0b013e31823eb07a PubMed DOI

Neale J, Smith AC. Cardiovascular risk factors following renal transplant. World J Transplant. (2015) 5(4):183–95. 10.5500/wjt.v5.i4.183 PubMed DOI PMC

Cheng XS, Van Wagner LB, Costa SP, Axelrod DA, Bangalore S, Norman SP, et al. Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates: a scientific statement from the American Heart Association: endorsed by the American Society of Transplantation. Circulation. (2022) 146(21):e299–324. 10.1161/CIR.0000000000001104 PubMed DOI PMC

Rangaswami J, Mathew RO, Parasuraman R, Tantisattamo E, Lubetzky M, Rao S, et al. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant. (2019) 34:760–73. 10.1093/ndt/gfz053 PubMed DOI

Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, et al. KDIGO on the evaluation and management of candidates for kidney transplantation. Transplantation. (2020) 104:708–14. 10.1097/TP.0000000000003137 PubMed DOI PMC

Kanigicherla DAK, Bhogal T, Stocking K, Chinnadurai R, Gray S, Javed S, et al. Non-invasive cardiac stress studies may not offer significant benefit in pre-kidney transplant evaluation: a retrospective cohort study. PLoS One. (2020) 15(10):e0240912. 10.1371/journal.pone.0240912 PubMed DOI PMC

Dilsizian V, Gewirtz H, Marwick TH, Kwong RY, Raggi P, Al-Mallah MH, et al. Cardiac imaging for coronary heart disease risk stratification in chronic kidney disease. JACC Cardiovasc Imaging. (2021) 14(3):669–82. 10.1016/j.jcmg.2020.05.035 PubMed DOI

Branny M. CT Coronary angiography and its role in diagnosing coronary disease. Interv Akut Kardiol. (2011) 10(SupplD):11–4.

Wang LW, Fahim MA, Hayen A, Mitchell RL, Lord SW, Baines LA, et al. Cardiac testing for coronary artery disease in potential kidney transplant recipients: a systematic review of test accuracy studies. Am J Kidney Dis. (2011) 57(3):476–87. 10.1053/j.ajkd.2010.11.018 PubMed DOI

Ko DT, Tu JV, Austin PC, Wijeysundera HC, Samasashvili Z, Guo H, et al. Prevalence and extent of obstructive coronary artery disease among patients undergoing elective coronary catheterization in New York state and Ontario. JAMA. (2013) 310(2):163–9. 10.1001/jama.2013.7834 PubMed DOI

König J, Möckel M, Mueller E, Bocksch W, Baid-Agrawal S, Babel N, et al. Risk-stratified cardiovascular screening including angiographic and procedural outcomes of percutaneous coronary interventions in renal transplant candidates. J Transplant. (2014) 2014:854397. 10.1155/2014/854397 PubMed DOI PMC

Baman JR, Knapper J, Raval Z, Harinstein ME, Friedewald JJ, Maganti K, et al. Preoperative noncoronary cardiovascular assessment and management of kidney transplant candidates. Clin J Am Soc Nephrol. (2019) 14:1670–6. 10.2215/CJN.03640319 PubMed DOI PMC

Tabriziani H, Baron P, Abudayyeh I, Lipkowitz M. Cardiac risk assessment for end-stage renal disease patients on the renal transplant waiting list. Clin Kidney J. (2019) 12(4):576–85. 10.1093/ckj/sfz039 PubMed DOI PMC

Hart A, Weir MR, Kasiske BL. Cardiovascular assessment in kidney transplantation. Kidney Int. (2015) 87(3):527–34. 10.1038/ki.2014.335 PubMed DOI

Gill JS. Screening transplant waitlist candidates for coronary artery disease. Clin J Am Soc Nephrol. (2019) 14:112–4. 10.2215/CJN.10510918 PubMed DOI PMC

De Lima JJ, Sabbaga E, Vieira MLC, de Paula FJ, Ianhez LE, Krieger EM, et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension. (2003) 43:263–8. 10.1161/01.HYP.0000087889.60760.87 PubMed DOI

Katta N, Balla S, Velagapudi P, Mittal M, Agrawal H, Kumar A, et al. Preoperative cardiac evaluation in kidney transplant patients: is coronary angiography superior? A focused review. Adv Perit Dial. (2016) 32:32–8. PubMed

Charytan D, Kuntz RE, Mauri L, DeFilippi C. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. (2007) 49:409–16. 10.1053/j.ajkd.2006.11.042 PubMed DOI

Palepu S, Prasad R. Screening for cardiovascular disease before kidney transplantation. World J Transplant. (2015) 5(4):276–86. 10.5500/wjt.v5.i4.276 PubMed DOI PMC

Bangalore S, Maron DJ, O’Brien SM, Fleg JL, Kretov EI, Briguori C, et al. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. (2020) 382:1608–18. 10.1056/NEJMoa1915925 PubMed DOI PMC

De Lima JJG, Gowdak LHW, de Paula FJ, Ianhez LE, Ramires JAF, Krieger EM. Validation of a strategy to diagnose coronary artery disease and predict cardiac events in high-risk renal transplant candidates. Coron Artery Dis. (2010) 21:164–7. 10.1097/MCA.0b013e328332ee5e PubMed DOI

Kumar N, Baker CSR, Chan K, Duncan N, Malik I, Frankel A, et al. Cardiac survival after pre-emptive coronary angiography in transplant patients and those awaiting transplantation. Clin J Am Soc Nephrol. (2011) 6(8):1912–9. 10.2215/CJN.08680910 PubMed DOI PMC

Kahn MR, Fallahi A, Kim MC, Robbins MJ. Coronary artery disease in a large renal transplant population: implications for management. Am J Transplant. (2011) 11(12):2665–74. 10.1111/j.1600-6143.2011.03734.x PubMed DOI

Nevis IF, Matthew A, Novick RJ, Parikh CR, Devereaux PJ, Natarajan MK, et al. Optimal method of coronary revascularization in patients receiving dialysis: systematic review. Clin J Am Soc Nephrol. (2009) 4:369–78. 10.2215/CJN.02640608 PubMed DOI PMC

Tavakol M, Ashraf S, Brener SJ. Risks and complications of coronary angiography: a comprehensive review. Glob J Health Sci. (2012) 4(1):65–93. 10.5539/gjhs.v4n1p65 PubMed DOI PMC

Janousek R, Krajina A, Peregrin JH, Dusilova-Sulkova S, Renc O, Hajek J, et al. Effect of intravascular iodinated contrast media on natural course of end-stage renal disease progression in hemodialysis patients: a prospective study. Cardiovasc Intervent Radiol. (2010) 33(1):61–6. 10.1007/s00270-009-9715-3 PubMed DOI

Moranne O, Willoteaux S, Pagniez D, Dequiedt P, Boulanger E. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant. (2006) 21(4):1040–5. 10.1093/ndt/gfi327 PubMed DOI

Oloko A, Taireja H, Davis A, McCormick B, Clark E, Akbari A, et al. Does iodinated contrast affect residual renal function in dialysis patients? a systematic review and meta-analysis. Nephron. (2020) 144(4):176–84. 10.1159/000505576 PubMed DOI

Nielsen YW, Thomsen HS. Current evidence of contrast medium-induced nephropathy (CIN) after administration of low-osmolarity iodine-based contrast agents. Curr Radiol Rep. (2017) 5:52. 10.1007/s40134-017-0244-6 DOI

Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayer WC. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol. (2012) 23(12):2042–9. 10.1681/ASN.2012060554 PubMed DOI PMC

Chan W, Ivanov J, Ko D, Fremes S, Rao V, Jolly S, et al. Clinical outcomes of treatment by percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with chronic kidney disease undergoing index revascularization in Ontario. Circ Cardiovasc Interv . (2015) 8:8. 10.1161/CIRCINTERVENTIONS.114.001973 PubMed DOI

Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA. Survival after coronary revascularization among patients with kidney disease. Circulation. (2004) 110(14):1890–5. 10.1161/01.CIR.0000143629.55725.D9 PubMed DOI

Shroff GR, Herzog CA. Coronary revascularization in patients with CKD stage 5D: pragmatic considerations. J Am Soc Nephrol. (2016) 27:3521–9. 10.1681/ASN.2016030345 PubMed DOI PMC

Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Eng J Med. (2015) 372:1213–22. 10.1056/NEJMoa1412168 PubMed DOI

Zoccali C, Benedetto F, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, et al. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol. (2004) 15:1029–37. 10.1097/01.asn.0000117977.14912.91 PubMed DOI

Wang AY, Wang M, Lam CW, Chan HIS, Zhang Y, Sanderson JE. Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease. Hypertension. (2008) 52:107–14. 10.1161/HYPERTENSIONAHA.108.112334 PubMed DOI

Lenihan CR, Montez-Rath ME, Scandling JD, Turakhia P, Winkelmayer WC. Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. Am J Transplant. (2013) 62(5):877–9. 10.1111/ajt.12197 PubMed DOI PMC

Jeloka TK, Ross H, Smith R, Huang M, Fenton S, Cattran D, et al. Renal transplant outcome in high cardiovascular risk recipients. Clin Transplant. (2007) 21:609–14. 10.1111/j.1399-0012.2007.00695.x PubMed DOI

Albakr RB, Bargman JM. A comparison of hemodialysis and peritoneal dialysis in patients with cardiovascular disease. Cardiol Clin. (2021) 39(3):447–53. 10.1016/j.ccl.2021.04.013 PubMed DOI

Banshodani M, Kawanishi H, Moriishi M, Shintaku S, Tsuchiya S. Association between dialysis modality and cardiovascular diseases: a comparison between peritoneal dialysis and hemodialysis. Blood Purif. (2020) 49(3):302–9. 10.1159/000504040 PubMed DOI

Refaat H, Sany D, Mohab A, Ezzat H. Comparing dialysis modality and cardiovascular mortality in patients on hemodialysis and peritoneal dialysis. Adv Perit Dial. (2016) 32:22–31. PubMed

Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abott KC. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis. (2003) 41(6):1267–77. 10.1016/s0272-6386(03)00359-7 PubMed DOI

Satyan S, Rocher LL. Impact of kidney transplantation on the progression of cardiovascular disease. Adv Chronic Kidney Dis. (2004) 11(3):274–93. 10.1053/j.arrt.2004.04.010 PubMed DOI

Lentine KL, Xiao HX, Brennan DC, Schnitzler MA, Villainess TC, Abbott KC, et al. The impact of kidney transplantation on heart failure risk varies with candidate body mass index. Am Heart J. (2009) 158(6):972–82. 10.1016/j.ahj.2009.10.009 PubMed DOI PMC

Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol. (2005) 45(7):1051–60. 10.1016/j.jacc.2004.11.061 PubMed DOI

Edmonston DL, Parikh KS, Rajagopal S, Shaw LK, Abraham D, Grabner A, et al. Pulmonary hypertension subtypes and mortality in CKD. Am J Kidney Dis. (2020) 75(5):713–24. 10.1053/j.ajkd.2019.08.027 PubMed DOI PMC

Issa N, Krowka MJ, Griffin MD, Hickson LJ, Stegall MD, Cosio F. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation. (2008) 86(10):1384–8. 10.1097/TP.0b013e318188d640 PubMed DOI

Naranjo M, Lo KB, Mezue K, Rangaswami J. Effects of pulmonary hypertension and right ventricular function in short and long-term kidney function. Current Cardiol Rev. (2019) 15(1):3–11. 10.2174/1573403X14666181008154215 PubMed DOI PMC

Lentine KL, Villines TC, Axelrod D, Kaviratne S, Weir MR, Costa SP. Evaluation and management of pulmonary hypertension in KTR: concepts and controversies. Transplantation. (2017) 101(1):166–81. 10.1097/TP.0000000000001043 PubMed DOI

Ewing EC, Edwards AR. Cardiovascular disease assessment prior to kidney transplantation. Methodist DeBakey Cardiovasc J. (2022) 18(4):50–61. 10.14797/mdcvj.1117 PubMed DOI PMC

Siddiqui MU, Junarta J, Marhefka GD. Coronary revascularization versus optimal medical therapy in renal transplant candidates with coronary artery disease: a systematic review and meta-analysis. J Am Heart Assoc. (2022) 11(4):e023548. 10.1161/JAHA.121.023548 PubMed DOI PMC

Roberts CA, Stern DL, Radio SJ. Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. Transplantation. (2002) 74(6):817–21. 10.1097/00007890-200209270-00015 PubMed DOI

Choudhary R, Sastry BKS. Subramanyam. Int J Cardiol. (2005) 105(3):327–31. 10.1016/j.ijcard.2005.04.006 PubMed DOI

Elezaby A, Dexheimer R, Sallam K. Cardiovascular effects of immunosuppression agents. Front Cardiovasc Med. (2022) 9:981838. 10.3389/fcvm.2022.981838 PubMed DOI PMC

KDIGO Clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. (2020) 104:4S. PubMed